NASDAQ:TRIB

Trinity Biotech - TRIB Stock Forecast, Price & News

$1.21

+0.01 (+0.83%)

(As of 10/4/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.18
▼
$1.28
50-Day Range: $1.05
▼
$1.41
52-Week Range: $0.86
▼
$2.50

Volume: 41,933 shs
Average Volume: 40,332 shs
Market Capitalization: $46.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Trinity Biotech (NASDAQ:TRIB) Stock

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Receive TRIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trinity Biotech and its competitors with MarketBeat's FREE daily newsletter.

TRIB Stock News Headlines

October 5, 2022 | americanbankingnews.com

Trinity Biotech (NASDAQ:TRIB) Earns Buy Rating from Analysts at StockNews.com

October 3, 2022 | benzinga.com

Trinity Industries, Inc. Announces $1.8B Multi-Year Railcar Order

October 3, 2022 | finance.yahoo.com

Trinity Biotech Announces The Appointment of Aris Kekedjian As Chairman and CEO

October 1, 2022 | seekingalpha.com

TRIB Trinity Biotech plc

September 30, 2022 | finance.yahoo.com

Trinity Biotech Announces Results of AGM

September 28, 2022 | americanbankingnews.com

Trinity Biotech (NASDAQ:TRIB) Now Covered by Analysts at StockNews.com

August 28, 2022 | finance.yahoo.com

Is There Now An Opportunity In Trinity Biotech plc (NASDAQ:TRIB)?

July 18, 2022 | finance.yahoo.com

Estimating The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

July 10, 2022 | msn.com

Revenues fall at Bray-based Trinity Biotech as Covid test sales decline

June 30, 2022 | seekingalpha.com

Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M

June 30, 2022 | seekingalpha.com

Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q1 2022 Results - Earnings Call Transcript

June 30, 2022 | finance.yahoo.com

Trinity Biotech Announces Quarter 1 2022 Financial Results

June 29, 2022 | uk.finance.yahoo.com

Trinity Biotech plc to Announce First Quarter Fiscal Year 2022 Financial Results

June 29, 2022 | finance.yahoo.com

Trinity Biotech plc to Announce First Quarter Fiscal Year 2022 Financial Results

May 20, 2022 | seekingalpha.com

Trinity biotech receives European approval for rapid COVID-19 antigen test

May 20, 2022 | finance.yahoo.com

Trinity Biotech Announces CE Mark of its 10-Minute Covid-19 Antigen Test

May 3, 2022 | finance.yahoo.com

Trinity Biotech Announces the Successful Closing of its Strategic Investment and Partnership With The MiCo Group of South Korea

April 13, 2022 | msn.com

Trinity Biotech takes $45m investment from South Korean MiCo

April 12, 2022 | seekingalpha.com

Trinity Biotech reports Q4 results

April 11, 2022 | seekingalpha.com

Trinity Biotech jumps 13% after Korea's MiCo acquires stake at premium

February 14, 2022 | msn.com

Trinity Biotech shares jump 6% premarket after WHO approves is rapid test for HIV

February 14, 2022 | seekingalpha.com

Trinity Biotech wins WHO approval for HIV screening test

February 14, 2022 | finance.yahoo.com

Trinity Biotech Announces the World Health Organisation Approval Of TrinScreen™ HIV

February 14, 2022 | finance.yahoo.com

Trinity Biotech shares jump 6% premarket after WHO approves its rapid test for HIV

January 27, 2022 | seekingalpha.com

Trinity Biotech closes refinancing transaction to settle debt

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive TRIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trinity Biotech and its competitors with MarketBeat's FREE daily newsletter.

TRIB Company Calendar

Last Earnings: 5/24/2021
Today: 10/05/2022
Next Earnings (Estimated): 12/21/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TRIB
CUSIP: N/A
CIK: 888721
Web: www.trinitybiotech.com
Phone: (531) 276-9800
Fax: 353-1276-9888
Employees: 543
Year Founded: 1992

Profitability

EPS (Most Recent Fiscal Year): ($0.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $880,000.00
Net Margins: -15.10%
Pretax Margin: -3.70%
Return on Equity: -347.92%
Return on Assets: 4.63%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.66
Quick Ratio: 1.80

Sales & Book Value

Annual Sales: $92.96 million
Price / Sales: 0.50
Cash Flow: $0.57 per share
Price / Cash Flow: 2.11
Book Value: ($0.02) per share
Price / Book: -60.50

Miscellaneous

Outstanding Shares: 38,110,000
Free Float: 34,983,000
Market Cap: $46.11 million
Optionable: Optionable
Beta: 1.32

Social Links

Key Executives

Mr. Ronan O'Caoimh (Age 66)
Chief Exec. Officer
Comp: $643k

Mr. John Gillard (Age 41)
CFO, Company Sec. & Exec. Director
Comp: $593k

Dr. James Walsh Ph.D. (Age 64)
Exec. Director
Comp: $20k

Mr. Simon Dunne (Age 48)
Chief Accounting Officer

Ms. Eibhlin Kelly (Age 38)
Chief Information Officer

Mr. Fernando Devia (Age 59)
Exec. VP of Sales

Mr. Sanjiv Suri (Age 63)
Sr. VP of Global Sales & GM of North America

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TRIB Stock - Frequently Asked Questions

How have TRIB shares performed in 2022?: Trinity Biotech's stock was trading at $1.43 on January 1st, 2022. Since then, TRIB stock has decreased by 15.4% and is now trading at $1.21.
View the best growth stocks for 2022 here.
When is Trinity Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, December 21st 2022.
View our TRIB earnings forecast.
How were Trinity Biotech's earnings last quarter?: Trinity Biotech plc (NASDAQ:TRIB) posted its quarterly earnings results on Monday, May, 24th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.03. The business earned $25.59 million during the quarter. Trinity Biotech had a negative net margin of 15.10% and a negative trailing twelve-month return on equity of 347.92%.
What is Ronan O'Caoimh's approval rating as Trinity Biotech's CEO?: 20 employees have rated Trinity Biotech Chief Executive Officer Ronan O'Caoimh on Glassdoor.com. Ronan O'Caoimh has an approval rating of 8% among the company's employees. This puts Ronan O'Caoimh in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Trinity Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Trinity Biotech investors own include Gilead Sciences (GILD), Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Netflix (NFLX), Pfizer (PFE), QUALCOMM (QCOM), Energy Transfer (ET) and Exxon Mobil (XOM).
What is Trinity Biotech's stock symbol?: Trinity Biotech trades on the NASDAQ under the ticker symbol "TRIB."
How do I buy shares of Trinity Biotech?: Shares of TRIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Trinity Biotech's stock price today?: One share of TRIB stock can currently be purchased for approximately $1.21.
How much money does Trinity Biotech make?: Trinity Biotech (NASDAQ:TRIB) has a market capitalization of $46.11 million and generates $92.96 million in revenue each year. The company earns $880,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.
How many employees does Trinity Biotech have?: The company employs 543 workers across the globe.
How can I contact Trinity Biotech?: Trinity Biotech's mailing address is IDA BUSINESS PARK BRAY, WICKLOW L2, . The official website for the company is www.trinitybiotech.com. The company can be reached via phone at (531) 276-9800, via email at kevin.tansley@trinitybiotech.com, or via fax at 353-1276-9888.

This page (NASDAQ:TRIB) was last updated on 10/5/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial